Peter De Cruz on the PREDICT-UC trial of intensified versus standard dose infliximab for steroid-refractory acute severe ulcerative colitis

Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.

Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00200-0?dgcid=buzzsprout_icw_podcast_generic_langas

Continue this conversation on social!

Follow us today at...

https://bsky.app/profile/lancetgastrohep.bsky.social

https://www.linkedin.com/company/langastro/

https://instagram.com/thelancetgroup

https://facebook.com/thelancetmedicaljournal

https://youtube.com/thelancettv

The Lancet Gastroenterology & Hepatology in conversation with...  is part of the Lancet Group podcast offering. 

Editorial team: editor-in-chief Rob Brierley, deputy editor Aisling O'Brien, and senior editor Bethany Gomersall

Podcast editing: Matteo Simonetti

Visit https://www.thelancet.com/multimedia to learn more about our multimedia offering. 

Find the best science for better lives at https://www.thelancet.com/

Follow us today at... x.com/LancetGastroHep bsky.app/lancetgastrohep.bsky.social Linkedin.com Instagram Facebook youtube.com/thelancettv